European Heart Journal Advance Access originally published online on March 11, 2008
European Heart Journal 2008 29(7):849-858; doi:10.1093/eurheartj/ehn070
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Ultrasound imaging techniques for the evaluation of cardiovascular therapies
Department of Vascular Medicine, Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
Received 19 December 2006; revised 24 January 2008; accepted 1 February 2008; online publish-ahead-of-print 11 March 2008.
* Corresponding author. Tel: +31 20 566 6612, Fax: +31 20 566 9343. Email: j.j.kastelein{at}amc.uva.nl/ paul.hassan{at}envisionpharma.com
Cardiovascular disease remains a substantial cause of morbidity and mortality in the developed world, and is becoming an increasingly important cause of death in developing countries too. While current cardiovascular treatments can help to reduce this disease burden, a substantial number of patients still retain a high risk of experiencing a life-threatening cardiovascular event. Thus, the development of new therapies capable of reducing this residual risk remains an important healthcare objective. The time taken to bring new therapies to the patient in need is lengthened by the unavoidable requirement to demonstrate a statistically significant benefit in terms of clinical events beyond that achievable with current treatments. However, clinical trials utilizing surrogate endpoints—biomarkers of disease progression that manifest before potentially fatal cardiovascular events occur—have the potential to enhance the process of drug development by enabling a statistically sound assessment of the efficacy of new therapies several years in advance of the availability of data from clinical endpoint trials. Two vascular ultrasound imaging techniques, measurement of carotid intima-media thickness (CIMT) and intravascular ultrasound (IVUS) of the coronary arteries, are increasingly being used to assess novel cardiovascular therapies in surrogate endpoint trials forming integral components of larger trial programmes utilizing both surrogate and clinical endpoints. The rationale for the use of CIMT- and IVUS-based surrogates, with supporting evidence from historical and recent trials, is presented in this review article.
Key Words: Cardiovascular disease • Coronary heart disease • Atherosclerosis • Intravascular ultrasound • B-mode ultrasound • Carotid intima-media thickness
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  V O Puntmann How-to guide on biomarkers: biomarker definitions, validation and applications with examples from cardiovascular disease Postgrad. Med. J., October 1, 2009; 85(1008): 538 - 545. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Mathur, C. Malkin, B. Saeed, R Muthusamy, T H. Jones, and K. Channer Long-term benefits of testosterone replacement therapy on angina threshold and atheroma in men Eur. J. Endocrinol., September 1, 2009; 161(3): 443 - 449. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A L. Gould, J. Koglin, R. P Bain, C.-A. Pinto, Y. B Mitchel, R. C Pasternak, and A. Sapre Effects of sources of variability on sample sizes required for RCTs, applied to trials of lipid-altering therapies on carotid artery intima-media thickness Clinical Trials, August 1, 2009; 6(4): 305 - 319. [Abstract] [PDF]
|
|
|
|
 |
|
 G. S. Kassab, J. S. Choy, M. Svendsen, A. K. Sinha, M. Alloosh, M. Sturek, Y. Huo, G. E. Sandusky, and J. Hermiller A novel system for the reconstruction of a coronary artery lumen profile in real time: a preclinical validation Am J Physiol Heart Circ Physiol, July 1, 2009; 297(1): H485 - H492. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Pasterkamp Imaging of de novo atherosclerotic arterial remodeling: clinical sense or research sensibility? J. Am. Coll. Cardiol., May 5, 2009; 53(18): 1716 - 1717. [Full Text] [PDF]
|
|